Japan Personalized Medicine Market Size & Outlook, 2025-2033
The personalized medicine market in Japan is expected to reach a projected revenue of US$ 65,848.6 million by 2033. A compound annual growth rate of 9.9% is expected of Japan personalized medicine market from 2025 to 2033.
The Japan personalized medicine market generated a revenue of USD 28,873.1 million in 2024 and is expected to reach USD 65,848.6 million by 2033.
The Japan market is expected to grow at a CAGR of 9.9% from 2025 to 2033.
In terms of segment, personalized nutrition & wellness was the largest revenue generating product in 2024.
PM Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Personalized medicine market data book summary
Market revenue in 2024
USD 28,873.1 million
Market revenue in 2033
USD 65,848.6 million
Growth rate
9.9% (CAGR from 2025 to 2033)
Largest segment
Personalized nutrition & wellness
Fastest growing segment
PM Therapeutics
Historical data
2021 - 2023
Base year
2024
Forecast period
2025 - 2033
Quantitative units
Revenue in USD million
Market segmentation
PM Diagnostics, PM Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness
Key market players worldwide
GE HealthCare Technologies Inc Common Stock, Illumina Inc, Asure Software Inc, Abbott Laboratories, Danaos Corp, Exact Sciences Corp, Danaher Corp, Amgen Inc, Qiagen NV, Exagen Inc Ordinary Shares, Quest Diagnostics Inc, Biogen Inc, Genelux Corp, International Business Machines Corp, Genentech, 23andMe Holding Co Class A
Other key industry trends
In terms of revenue, Japan accounted for 5.1% of the global personalized medicine market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China personalized medicine market is projected to lead the regional market in terms of revenue in 2033.
China is the fastest growing regional market in Asia Pacific and is projected to reach USD 77,885.4 million by 2033.
Japan’s personalized medicine market accounted for a significant revenue share in 2020. This share is due to the outcome of an active expansion strategy under execution by several market participants to strengthen their position in the Asia Pacific region.
Japan is the first country to approve Rozlytrek—a precision medicine offered by Roche. In June 2019, the Ministry of Health, Labour and Welfare of Japan approved Rozlytrek indicated for the management of neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors in patients.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Personalized Medicine Market Outlook will help companies and investors design strategic landscapes.
Personalized Nutrition & Wellness was the largest segment with a revenue share of 34.01% in 2024.
Horizon Databook has segmented the Japan personalized medicine market based on pm diagnostics, pm therapeutics, personalized medical care, personalized nutrition & wellness covering the revenue growth of each sub-segment from 2021 to 2033.
Japan’s personalized medicine market accounted for a significant revenue share in 2020. This share is due to the outcome of an active expansion strategy under execution by several market participants to strengthen their position in the Asia Pacific region.
Japan is the first country to approve Rozlytrek—a precision medicine offered by Roche. In June 2019, the Ministry of Health, Labour and Welfare of Japan approved Rozlytrek indicated for the management of neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors in patients.
Japan Personalized Medicine Market Product Outlook (Revenue, USD Million , 2021-2033)
PM Diagnostics
PM Therapeutics
Personalized Medical Care
Personalized Nutrition & Wellness
Reasons to subscribe to Personalized Medicine Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Personalized Medicine Market Outlook databook
Our clientele includes a mix of Personalized Medicine Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Personalized Medicine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Personalized Medicine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Personalized Medicine Market, 2021-2033 (US$M)